Novartis has agreed to sell its Indian generics and prescription drugs unit to a private equity-led consortium for $159 million, as part of a broader strategy review. This move underscores the company's focus on core businesses and divesting less strategic assets. Content creators should note this trend towards consolidation and strategic asset divestment in the pharmaceutical industry.
Read the full article at Endpoints News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.



